) [153]. This method is at the moment not scalable because it relies on costly startup substrates which may be employed to supply psilocybin in much less expensive chemical synthesis methodologies. A methodology for de novo manufacture of psilocybin and tryptamine derivatives in Saccharomyces cerevisiae,Speedy and sustained symptom reduction pursui